Boothbay Fund Management LLC Takes $548,000 Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Boothbay Fund Management LLC purchased a new position in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 537,219 shares of the biopharmaceutical company's stock, valued at approximately $548,000. Boothbay Fund Management LLC owned approximately 0.26% of Sangamo Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in SGMO. Golden State Equity Partners lifted its holdings in Sangamo Therapeutics by 2,592.3% during the 4th quarter. Golden State Equity Partners now owns 325,684 shares of the biopharmaceutical company's stock worth $332,000 after buying an additional 313,587 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Sangamo Therapeutics by 14.6% in the 3rd quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company's stock valued at $1,853,000 after buying an additional 272,123 shares during the last quarter. EAM Investors LLC acquired a new stake in Sangamo Therapeutics during the 4th quarter worth $256,000. Virtu Financial LLC acquired a new position in Sangamo Therapeutics in the third quarter valued at $150,000. Finally, State Street Corp increased its position in shares of Sangamo Therapeutics by 28.0% during the third quarter. State Street Corp now owns 664,621 shares of the biopharmaceutical company's stock worth $576,000 after purchasing an additional 145,400 shares in the last quarter. Hedge funds and other institutional investors own 56.93% of the company's stock.

Sangamo Therapeutics Price Performance

Sangamo Therapeutics stock traded down $0.01 during mid-day trading on Friday, reaching $0.73. The company had a trading volume of 1,932,647 shares, compared to its average volume of 8,586,445. The stock's 50-day simple moving average is $0.81 and its 200-day simple moving average is $1.38. The company has a market capitalization of $166.92 million, a P/E ratio of -0.97 and a beta of 1.46. Sangamo Therapeutics, Inc. has a 1 year low of $0.30 and a 1 year high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). The firm had revenue of $7.55 million for the quarter, compared to analysts' expectations of $11.70 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. On average, equities analysts forecast that Sangamo Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Analysts Set New Price Targets

SGMO has been the subject of several research analyst reports. HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Sangamo Therapeutics in a report on Monday, April 7th. Royal Bank of Canada reissued a "sector perform" rating and set a $2.00 price target on shares of Sangamo Therapeutics in a report on Tuesday, March 18th. Finally, Truist Financial decreased their price objective on Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating for the company in a research report on Thursday, January 23rd. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Sangamo Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $5.17.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.